by Allogeneic stem cell transplantation, often called bone marrow transplantation, is a medical procedure where a person receives healthy stem cells from a genetically similar, but not identical, donor. These stem cells have the potential to develop into red or white blood cells or platelets. Stem cell transplantation is used in cancer treatment to replace damaged or destroyed bone marrow. Stem cells collected from peripheral blood, bone marrow, or umbilical cord blood can treat over 80 types of cancers and immune disorders. Stem cell products offer a non-invasive approach for blood cancers like leukemia and lymphoma. The global allogeneic stem cell transplantation market offers promising outcomes for patients with blood-related diseases.
The global Allogeneic Stem Cell Transplantation Market is estimated to be valued at US$ 3.9 Bn in 2023 and is expected to exhibit a CAGR of 7.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The growing popularity of regenerative medicine is expected to drive the market during the forecast period. Regenerative medicine utilizes stem cells and tissue engineering to repair and replace damaged tissues. Various research is exploring regenerative potential of stem cells to treat chronic illnesses like heart disease, diabetes, and neurodegenerative conditions. Umbilical cord banks are expanding globally due to the ease of procurement and lower risk of rejection compared to other stem cell sources. Increasing stem cell collection and storage facilities are providing viable alternatives to bone marrow transplantation. However, high costs of stem cell therapies and complex regulatory frameworks remain key challenges for industry players. Continuous research seeks safer and economical methods to unlock stem cell power.
Porter’s Analysis
Threat of new entrants: The risk of new entrants in the allogeneic stem cell transplantation market is moderate to high due to the huge investments required to enter the market.
Bargaining power of buyers: Buyers have moderate bargaining power as there are several suppliers of stem cell products and services in the market. Buyers can negotiate on the pricing and obtain discounts from suppliers.
Bargaining power of suppliers: The bargaining power of suppliers is moderate as there are several companies involved in stem cell manufacturing and research activities. Suppliers also have the threat of forward integration by companies.
Threat of new substitutes: Currently, there are limited treatment substitutes for allogeneic stem cell transplantation. Research is ongoing to develop better substitutes.
Competitive rivalry: The market is competitive with major players competing based on pricing, quality, innovation, and service.
Key Takeaways
The Global Allogeneic Stem Cell Transplantation Market Size is expected to grow at a CAGR of 7.3% during the forecast period of 2023 to 2030.
Regional analysis: North America dominates the market currently due to increased adoption, advanced healthcare infrastructure, and presence of key market players in the region. Asia Pacific shows high growth potential owing to rising healthcare spending, increasing cancer incidence, and growing medical tourism industry.
Key players: The key players operating in the allogeneic stem cell transplantation market are Merck & Co., Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Astrazeneca Plc., Fresenius Medical Care AG & CO. KGAA, and F. Hoffmann-la Roche Ltd. (Genentech, Inc.), among others. These key players are focusing on new product launches, expansions, partnerships and acquisitions to strengthen their market presence.
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.
